Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022

Copenhagen, Denmark, 6 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform that the Principal Investigator, Chief Surgeon Jane Skjøth-Rasmussen will be presenting the outstanding clinical data from the completed phase I/IIa trial with FG001 in patients with aggressive brain cancer undergoing surgery at the European Congress of Neurosurgery on 19 October 2022 in Belgrade, Serbia.

The release as fetched from its publisher. fluoguide.com ↗